Mercado de tratamento para a deficiência cognitiva ligeira (MCI) na América do Norte, por tipo de doença (MCI amnésico, MCI não amnésico), tipo de tratamento (medicamentos, terapêutica), via de administração (oral, parentérica, outros), tipo de medicamento (de marca, genéricos) , Tipo de género (masculino, feminino), Tipo de idade (criança, adulto, geriátrico), Utilizador final (hospitais, clínicas especializadas, assistência domiciliária, outros), Canal de distribuição (farmácias hospitalares, farmácias de retalho), País (EUA, Canadá, México) – Tendências e previsões da indústria até 2029
Análise de mercado e insights : Mercado de tratamento da deficiência cognitiva ligeira (MCI) na América do Norte
Espera-se que o mercado de tratamento do défice cognitivo ligeiro (MCI) ganhe crescimento de mercado no período previsto de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 9,0% no período previsto de 2022 a 2029 e está deverá atingir os 62.355,90 mil dólares até 2029. O amplo portefólio oferecido pelos principais players e a crescente consciencialização sobre o défice cognitivo ligeiro deverão atuar como impulsionadores do crescimento do mercado.
O défice cognitivo ligeiro (CCL) é uma fase inicial de perda de memória ou outra perda de capacidade cognitiva (como a linguagem ou a perceção visual/espacial) em indivíduos que mantêm a capacidade de realizar a maioria das atividades da vida diária de forma independente. O DCL pode desenvolver-se por vários motivos, e os indivíduos que vivem com DCL podem desenvolver demência. O DCL pode ser um estágio inicial do continuum da doença neurodegenerativa, incluindo o Alzheimer. Em alguns indivíduos, o DCL regressa à cognição normal ou mantém-se estável.
O défice cognitivo ligeiro (CCL) é caracterizado pelo comprometimento num único domínio cognitivo, geralmente a memória (CCL amnésico), ou comprometimento moderado em vários domínios cognitivos. A prevalência de DCL entre indivíduos que vivem em ambientes de cuidados continuados varia entre 5% a 10% em muitos lares de idosos, podendo chegar até aos 30%. A forma mais frequentemente encontrada de DCL é o tipo amnésico. Variantes menos comuns de DCL apresentam um comprometimento localizado de outros domínios cognitivos, como a disfunção executiva na degeneração lobar frontotemporal (DLFT).
Os principais fatores que impulsionam o crescimento do mercado global de tratamento do défice cognitivo ligeiro (CCL) são o aumento da população de doentes mais velhos e a expectativa é que a investigação contínua para encontrar a cura perfeita e eficaz impulsione o crescimento do mercado nos próximos tempos . No entanto, o elevado custo dos procedimentos terapêuticos e os riscos adversos associados aos produtos podem dificultar o crescimento do mercado.
O relatório de mercado de tratamento de défice cognitivo ligeiro (MCI) fornece detalhes sobre a quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado nacional e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado, aprovações de produtos, estratégias decisões, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado do Tratamento do Comprometimento Cognitivo Leve (CCL), contacte a Data Bridge Market Research para obter um resumo analítico. A nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o seu objetivo desejada.
Âmbito e dimensão do mercado de tratamento da deficiência cognitiva ligeira (MCI)
O mercado de tratamento para o défice cognitivo ligeiro (CCL) está segmentado com base no tipo de doença, tipo de tratamento, via de administração, tipo de medicamento, tipo de género, tipo de idade, canal de distribuição e utilizadores finais. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo de doença, o mercado de tratamento do défice cognitivo ligeiro (CCL) está segmentado em CCL amnésico e CCL não amnésico. Em 2022, prevê-se que o segmento da DCL amnésica domine o mercado global de tratamento do défice cognitivo ligeiro (DCL), devido ao aumento da população idosa em todo o mundo.
- Com base no tipo de tratamento, o mercado de tratamento para o défice cognitivo ligeiro (CCL) está segmentado em medicamentos e terapia. Em 2022, prevê-se que o segmento dos medicamentos domine o mercado global de tratamento do défice cognitivo ligeiro (CCL) devido ao seu impacto imediato e eficaz nos sintomas do CCL.
- Com base na via de administração, o mercado de tratamento para o défice cognitivo ligeiro (CCL) está segmentado em oral e parentérica, entre outros. Em 2022, prevê-se que o segmento oral domine o mercado global de tratamento do défice cognitivo ligeiro (CCL) devido à sua não invasividade, elevada adesão dos doentes, manuseamento prático e não exigência de condições estéreis específicas.
- Com base no tipo de medicamento, o mercado de tratamento para o défice cognitivo ligeiro (CCL) está segmentado em medicamentos de marca e genéricos. Em 2022, prevê-se que o segmento dos genéricos domine o mercado global de tratamento do défice cognitivo ligeiro (CCL) devido à relação custo-eficácia em comparação com os medicamentos de marca.
- Com base no género, o mercado de tratamento para o défice cognitivo ligeiro (CCL) está segmentado em masculino e feminino. Em 2022, prevê-se que o segmento masculino domine o mercado global de tratamento do défice cognitivo ligeiro (CCL) devido ao aumento das complicações de saúde mental observadas na população masculina.
- Com base na idade, o mercado de tratamento para o défice cognitivo ligeiro (CCL) está segmentado em infantil, adulto e geriátrico. Em 2022, prevê-se que o segmento geriátrico domine o mercado global de tratamento do défice cognitivo ligeiro (CCL) devido ao aumento da população idosa vulnerável, com a maior taxa de aumento na região asiática.
- Com base nos utilizadores finais, o mercado de tratamento do défice cognitivo ligeiro (CCL) está segmentado em hospitais, clínicas especializadas, cuidados domiciliários e outros. Em 2022, espera-se que o segmento hospitalar domine o mercado global de tratamento do défice cognitivo ligeiro (CCL) devido à maior consciencialização sobre tratamentos melhores e mais eficazes durante os internamentos hospitalares.
- Com base no canal de distribuição, o mercado de tratamento do défice cognitivo ligeiro (CCL) está segmentado em farmácias hospitalares e farmácias de retalho. Em 2022, prevê-se que o segmento da farmácia hospitalar domine o mercado global de tratamento do défice cognitivo ligeiro (CCL) devido ao aumento da interação com prescritores certificados e profissionais de saúde para a utilização de medicamentos antipsicóticos e pagamento garantido.
Análise de mercado a nível de país para o tratamento da deficiência cognitiva ligeira (MCI)
O mercado de tratamento para o défice cognitivo ligeiro (CCL) é analisado e são fornecidas informações sobre o tamanho do mercado por país, tipo de doença, tipo de tratamento, via de administração, tipo de medicamento, tipo de género, idade, canal de distribuição e utilizadores finais, conforme acima referenciado.
Os países abrangidos pelo relatório de mercado sobre o tratamento do défice cognitivo ligeiro (CCL) são os EUA, o Canadá e o México.
Espera-se que os EUA dominem o mercado de tratamento para o défice cognitivo ligeiro (CCL) devido à investigação em curso para encontrar a cura perfeita e eficaz.
A secção do relatório sobre os países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Pontos de dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade de marcas globais e os desafios enfrentados devido à grande ou escassa concorrência de marcas locais e nacionais, bem como o impacto dos canais de vendas, são considerados ao fornecer uma análise de previsão dos dados do país.
O crescimento das atividades estratégicas dos principais participantes do mercado para aumentar a consciencialização sobre o tratamento do défice cognitivo ligeiro (CCL) está a impulsionar o crescimento do mercado do tratamento do défice cognitivo ligeiro (CCL).
O mercado de tratamento para o défice cognitivo ligeiro (CCL) também fornece análises de mercado detalhadas para o crescimento de cada país num mercado específico. Além disso, fornece informações detalhadas sobre a estratégia dos participantes do mercado e a sua presença geográfica. Os dados estão disponíveis para o período histórico de 2011 a 2020.
Análise do cenário competitivo e da quota de mercado do tratamento do défice cognitivo ligeiro (MCI)
O cenário competitivo do mercado de tratamento para o défice cognitivo ligeiro (CCL) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produto, aprovações de produto, patentes, largura e amplitude do produto, domínio da aplicação, curva de vida da tecnologia. Os pontos de dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado de tratamento do défice cognitivo ligeiro (CCL).
Alguns dos principais participantes que operam no mercado do tratamento do défice cognitivo ligeiro (CCL) são a Pfizer Inc., a F. Hoffman La Roche Ltd, a Novartis AG, a Accord UK Ltd, a Dr. Reddy’s laboratorys Ltd, a Hikma Pharmaceuticals PLC, a Viatris Inc., Eisai . Co. Ltd., Sun Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma , UCB SA, Bélgica, e WOCKHARDT, entre outros.
Por exemplo,
- Em julho de 2021, a FDA aprovou o Biogen Aduhelm (aducanumab) para tratar doentes com doença de Alzheimer utilizando o caminho de aprovação acelerada
A colaboração, o lançamento de produtos, a expansão de negócios, prémios e reconhecimentos, joint ventures e outras estratégias do participante do mercado estão a aumentar a presença da empresa no mercado de tratamento do défice cognitivo ligeiro (CCL), o que também traz benefícios para o crescimento do lucro da organização.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 DISEASES TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE
4.2 PORTERS
5 EPIDEMIOLOGY
6 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: REGULATORY SCENARIO
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN VULNERABLE GERIATRIC POPULATION
7.1.2 INCREASE IN AIR POLLUTION IMPACTS COGNITIVE PERFORMANCE
7.1.3 INCREASING NATIONAL AND INTERNATIONAL INVESTMENTS IN RESEARCH AND DEVELOPMENT OF COGNITIVE DISORDERS TREATMENT
7.1.4 RISE IN INCIDENCE OF NON-COMMUNICABLE DISEASES DUE TO PHYSICAL INACTIVITY
7.2 RESTRAINTS
7.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT
7.2.2 SERIOUS ADVERSE RISK ASSOCIATED WITH MCI TREATMENT DRUGS
7.2.3 HIGH COST OF TREATMENT AND CARE MANAGEMENT IN MCI PATIENTS
7.3 OPPORTUNITIES
7.3.1 PROMOTING PATIENT MENTAL HEALTH PROGRAMS
7.3.2 INNOVATION IN ALTERNATIVE MILD COGNITIVE IMPAIRMENT TREATMENT
7.4 CHALLENGES
7.4.1 LONG PROCESS OF APPROVAL BY REGULATORY BODIES
7.4.2 LACK OF SKILLED PROFESSIONALS
8 COVID-19 IMPACT ON MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY
8.4 STRATEGIC DECISIONS BY MANUFACTURERS
8.5 CONCLUSION
9 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 AMNESTIC MCI
9.3 NON-AMNESTIC MCI
10 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 MEDICATION
10.2.1 CHOLINESTERASE INHIBITORS
10.2.1.1 DONEPEZIL
10.2.1.2 RIVASTIGMINE
10.2.1.3 OTHERS
10.2.2 BENZODIAZEPINES
10.2.2.1 DIAZEPAM
10.2.2.2 CLONAZEPAM
10.2.2.3 LORAZEPAM
10.2.2.4 TEMAZEPAM
10.2.2.5 ALPRAZOLAM
10.2.2.6 FLUNITRAZEPAM
10.2.2.7 FLURAZEPAM
10.2.2.8 ZOPICLONE
10.2.2.9 OTHERS
10.2.3 GLUTAMATE INHIBITORS
10.2.3.1 RILUZOLE
10.2.3.2 OTHERS
10.2.4 ANTIHISTAMINES
10.2.4.1 CETIRIZINE
10.2.4.2 BROMPHENIRAMINE
10.2.4.3 CHLORPHENIRAMINE
10.2.4.4 CLEMASTINE
10.2.4.5 DIPHENHYDRAMINE
10.2.4.6 FEXOFENADINE
10.2.4.7 LORATADINE
10.2.4.8 OTHERS
10.2.5 MAO INHIBITORS
10.2.5.1 ISOCARBOXAZID
10.2.5.2 PHENELZINE
10.2.5.3 SELEGILINE
10.2.5.4 TRANYLCYPROMINE
10.2.5.5 OTHERS
10.2.6 PROTON PUMP INHIBITORS
10.2.6.1 ESOMEPRAZOLE
10.2.6.2 LANSOPRAZOLE
10.2.6.3 OMEPRAZOLE
10.2.6.4 RABEPRAZOLE
10.2.6.5 PANTOPRAZOLE
10.2.6.6 OTHERS
10.2.7 ALTERNATE THERAPY
10.2.7.1 VITAMIN E
10.2.7.2 GINKO
10.2.7.3 OTHERS
10.2.7.4 OTHERS
10.3 THERAPY
10.3.1 COGNITIVE STIMULATION THERAPY
10.3.2 COGNITIVE BEHAVIORAL THERAPY (CBT)
11 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 SYRUP
11.2.3 OTHERS
11.3 PARENTERAL
11.3.1 INTRAVENOUS
11.3.2 INTRAMUSCULAR
11.3.3 OTHERS
11.4 OTHERS
12 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
13 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER
13.1 OVERVIEW
13.2 MALE
13.3 FEMALE
14 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE
14.1 OVERVIEW
14.2 GERIATRIC
14.3 ADULT
14.4 CHILD
15 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 HOMECARE
15.5 OTHERS
16 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.3.1 RETAIL SHOPS
16.3.2 ONLINE PHARMACY
17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 EISAI CO., LTD
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.1.5.1 PRODUCT LAUNCH
20.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 NOVARTIS AG
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 VIATRIS, INC
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 SUN PHARMACEUTICALS INDUSTRIES LTD
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 PFIZER INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENT
20.7 ASTRAZENECA
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.7.4.1 ACQUISITION
20.8 DR. REDDY’S LABORATORIES LTD.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 AUROBINDO PHARMA
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORFOLIO
20.9.4 RECENT DEVELOPMENT
20.9.4.1 PRODUCT APPROVAL
20.1 F.HOFFMANN-LA ROCHE LTD.
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 ABBVIE INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENT
20.11.4.1 DATA PRESENTATION
20.12 ACCORD-UK LTD
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 CIPLA INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENT
20.14 HIKMA PHARMACEUTICALS PLC
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE ANALYSIS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENTS
20.15 JOHNSON & JOHNSON SERVICES, INC.
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENT
20.16 JUBILANT PHARMA LIMITED
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 LANNETT
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENT
20.18 LUPIN
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENT
20.18.4.1 AGREEMENT
20.19 MALLINCKRODT PHARMACEUTICALS
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENT
20.21 UCB S.A., BELGIUM
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENT
20.22 WOCKHARDT
20.22.1 COMPANY SNAPSHOT
20.22.2 REVENUE ANALYSIS
20.22.3 PRODUCT PORTFOLIO
20.22.4 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Lista de Tabela
TABLE 1 COMMON BENZODIAZEPINES AVAILABLE IN THE U.S.-
TABLE 2 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 3 NORTH AMERICA AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 NORTH AMERICA NON-AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 5 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 6 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 8 NORTH AMERICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 9 NORTH AMERICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 10 NORTH AMERICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 11 NORTH AMERICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 12 NORTH AMERICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 13 NORTH AMERICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 14 NORTH AMERICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 15 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 16 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 18 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 19 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 20 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 21 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 22 NORTH AMERICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 23 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 24 NORTH AMERICA GENERICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 25 NORTH AMERICA BRANDED IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 26 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 27 NORTH AMERICA MALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 28 NORTH AMERICA FEMALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 29 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 30 NORTH AMERICA GERIATRIC IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 31 NORTH AMERICA ADULT IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 32 NORTH AMERICA CHILD IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 34 NORTH AMERICA HOSPITALS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 NORTH AMERICA SPECIALITY CLINICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 NORTH AMERICA HOMECARE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 37 NORTH AMERICA OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 39 NORTH AMERICA HOSPITAL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 41 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 42 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 43 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 44 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 45 NORTH AMERICA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 46 NORTH AMERICA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 47 NORTH AMERICA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 48 NORTH AMERICA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 49 NORTH AMERICA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 50 NORTH AMERICA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 51 NORTH AMERICA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 52 NORTH AMERICA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 53 NORTH AMERICA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 54 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 55 NORTH AMERICA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 56 NORTH AMERICA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 57 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 58 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 59 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 60 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 61 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 62 NORTH AMERICA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 63 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 64 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 65 U.S. MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 66 U.S. CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 67 U.S. BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 68 U.S. GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 69 U.S. MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 70 U.S. PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 71 U.S. ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 72 U.S. ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 73 U.S. THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 74 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 75 U.S. ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 76 U.S. PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 77 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 78 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 79 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 80 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 81 U.S. MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 82 U.S. RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 83 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 84 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 85 CANADA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 86 CANADA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 87 CANADA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 88 CANADA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 89 CANADA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 90 CANADA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 91 CANADA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 92 CANADA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 93 CANADA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 94 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 95 CANADA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 96 CANADA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 97 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 98 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 99 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 100 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 101 CANADA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 102 CANADA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 103 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
TABLE 104 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 105 MEXICO MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 106 MEXICO CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 107 MEXICO BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 108 MEXICO GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 109 MEXICO MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 110 MEXICO PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 111 MEXICO ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 112 MEXICO ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 113 MEXICO THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)
TABLE 114 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 115 MEXICO ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 116 MEXICO PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
TABLE 117 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)
TABLE 118 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)
TABLE 119 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)
TABLE 120 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 121 MEXICO MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 122 MEXICO RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
Lista de Figura
FIGURE 1 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: END USERS COVERAGE GRID
FIGURE 8 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE AND ASIA-PACIFIC IS ESTIMATED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 ONGOING RESEARCH TO INCREASE THE THERAPEUTICS APPLICATION IS EXPECTED TO DRIVE THE NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 AMNESTIC MCI SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET
FIGURE 15 DISEASE BURDEN BY RISK FACTOR, WORLDWIDE, 2019
FIGURE 16 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2021
FIGURE 17 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2020-2029 (USD THOUSAND)
FIGURE 18 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2021
FIGURE 21 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD THOUSAND)
FIGURE 22 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 25 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)
FIGURE 26 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2021
FIGURE 29 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2020-2029 (USD THOUSAND)
FIGURE 30 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 32 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2021
FIGURE 33 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2020-2029 (USD THOUSAND)
FIGURE 34 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, CAGR (2022-2029)
FIGURE 35 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 36 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2021
FIGURE 37 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2020-2029 (USD THOUSAND)
FIGURE 38 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, CAGR (2022-2029)
FIGURE 39 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 40 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2021
FIGURE 41 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2020-2029 (USD THOUSAND)
FIGURE 42 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
FIGURE 46 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 49 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 50 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 NORTH AMERICA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
